1. Home
  2. ZDAI vs TPST Comparison

ZDAI vs TPST Comparison

Compare ZDAI & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ZDAI

Primega Group Holdings Limited Ordinary Shares

SELL

Current Price

$1.23

Market Cap

11.6M

ML Signal

SELL

Logo Tempest Therapeutics Inc.

TPST

Tempest Therapeutics Inc.

HOLD

Current Price

$0.29

Market Cap

13.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZDAI
TPST
Founded
2022
2011
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
General Bldg Contractors - Nonresidential Bldgs
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.6M
13.7M
IPO Year
2023
2012

Fundamental Metrics

Financial Performance
Metric
ZDAI
TPST
Price
$1.23
$0.29
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
3.5K
★ 182.0K
Earning Date
08-17-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $295,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.20
$0.29
52 Week High
$11.48
$4.22

Technical Indicators

Market Signals
Indicator
ZDAI
TPST
Relative Strength Index (RSI) 44.62 20.25
Support Level $1.10 N/A
Resistance Level $1.61 $0.56
Average True Range (ATR) 0.13 0.05
MACD -0.00 0.00
Stochastic Oscillator 21.43 4.46

Price Performance

Historical Comparison
ZDAI
TPST

About ZDAI Primega Group Holdings Limited Ordinary Shares

DirectBooking Technology Co Ltd, formerly Primega Group Holdings Ltd is engaged in transportation services. It operates in the Hong Kong construction industry, mainly handling the transportation of materials excavated from construction sites. Its services principally comprise (i) soil and rock transportation services; (ii) diesel oil trading; and (iii) construction works, which mainly include ELS works and bored piling. The company provide services as a subcontractor to other construction contractors in Hong Kong. Maximum revenue is generated from soil and rock transportation services.

About TPST Tempest Therapeutics Inc.

Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.

Share on Social Networks: